Conatus Announces Completion of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
May 16, 2017 16:05 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, May 16, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver...
Conatus Announces Pricing of Public Offering of Common Stock
May 11, 2017 09:01 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, May 11, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver...
Conatus Announces Proposed Public Offering of Common Stock
May 10, 2017 16:01 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, May 10, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver...
Conatus Pharmaceuticals Reports First Quarter 2017 Financial Results and Program Updates
May 04, 2017 16:05 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the first quarter ended March 31, 2017, and provided updates on its...
Conatus Announces Exercise of License Option for Global Development and Commercialization of Emricasan Following Notice of Initiation of Phase 2b ENCORE-LF Clinical Trial in NASH Cirrhosis
May 04, 2017 01:15 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that Novartis has exercised its option to an exclusive license for the global development and...
Conatus Pharmaceuticals to Report First Quarter 2017 Financial Results
April 27, 2017 16:05 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, April 27, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the first quarter ended March 31, 2017, after the...
Conatus Posters at EASL Meeting Address MELD Score Dynamics and Outcomes in Decompensated Liver Cirrhosis Patients, Including NASH Patients, Awaiting Liver Transplantation
April 21, 2017 02:00 ET
|
Conatus Pharmaceuticals Inc.
AMSTERDAM, the Netherlands, April 21, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced that two posters co-authored by Conatus employees are being presented today at The...
Conatus to Present at Upcoming Investor Conferences
March 27, 2017 07:30 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, March 27, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced the company’s scheduled presentations at two upcoming investor conferences in New York: H.C....
Conatus Pharmaceuticals Reports 2016 Financial Results and Program Updates
March 15, 2017 16:05 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, March 15, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the fourth quarter and full year ended December 31, 2016, and provided...
Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2016 Financial Results
March 08, 2017 16:05 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, March 08, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the fourth quarter and full year ended December 31,...